Click here to close
Hello! We notice that you are using Internet Explorer, which is not supported by Xenbase and may cause the site to display incorrectly.
We suggest using a current version of Chrome,
FireFox, or Safari.
Verapamil inhibits Kir2.3 channels by binding to the pore and interfering with PIP2 binding.
Xynogalos P
,
Rahm AK
,
Fried S
,
Chasan S
,
Scherer D
,
Seyler C
,
Katus HA
,
Frey N
,
Zitron E
.
???displayArticle.abstract???
The inwardly rectifying potassium current of the cardiomyocyte (IK1) is the main determinant of the resting potential. Ion channels Kir2.1, Kir2.2, and Kir2.3 form tetramers and are the molecular correlate of macroscopic IK1 current. Verapamil is an antiarrhythmic drug used to suppress atrial and ventricular arrhythmias. Its primary mechanism of action is via blocking calcium channels. In addition, it has been demonstrated to block IK1 current and the Kir2.1 subunit. Its effect on other subunits that contribute to IK1 current has not been studied to date. We therefore analyzed the effect of verapamil on the Kir channels 2.1, 2.2, and 2.3 in the Xenopus oocyte expression system. Kir2.1, Kir2.2, and Kir2.3 channels were heterologously expressed in Xenopus oocytes. Respective currents were measured with the voltage clamp technique and the effect of verapamil on the current was measured. At a concentration of 300 µM, verapamil inhibited Kir2.1 channels by 41.36% ± 2.7 of the initial current, Kir2.2 channels by 16.51 ± 3.6%, and Kir2.3 by 69.98 ± 4.2%. As a verapamil effect on kir2.3 was a previously unknown finding, we analyzed this effect further. At wash in with 300 µM verapamil, the maximal effect was seen within 20 min of the infusion. After washing out with control solution, there was only a partial current recovery. The current reduction from verapamil was the same at - 120 mV (73.2 ± 3.7%), - 40 mV (85.5 ± 6.5%), and 0 mV (61.5 ± 10.6%) implying no voltage dependency of the block. Using site directed mutations in putative binding sites, we demonstrated a decrease of effect with pore mutant E291A and absence of verapamil effect for D251A. With mutant I214L, which shows a stronger affinity for PIP2 binding, we observed a normalized current reduction to 61.9 ± 0.06% of the control current, which was significantly less pronounced compared to wild type channels. Verapamil blocks Kir2.1, Kir2.2, and Kir2.3 subunits. In Kir2.3, blockade is dependent on sites E291 and D251 and interferes with activation of the channel via PIP2. Interference with these sites and with PIP2 binding has also been described for other Kir channels blocking drugs. As Kir2.3 is preferentially expressed in atrium, a selective Kir2.3 blocking agent would constitute an interesting antiarrhythmic concept.
Amorós,
Propafenone blocks human cardiac Kir2.x channels by decreasing the negative electrostatic charge in the cytoplasmic pore.
2013, Pubmed
Amorós,
Propafenone blocks human cardiac Kir2.x channels by decreasing the negative electrostatic charge in the cytoplasmic pore.
2013,
Pubmed
Anumonwo,
Cardiac strong inward rectifier potassium channels.
2010,
Pubmed
Bergson,
Verapamil block of T-type calcium channels.
2011,
Pubmed
Daoud,
Effect of verapamil and procainamide on atrial fibrillation-induced electrical remodeling in humans.
1997,
Pubmed
Du,
Characteristic interactions with phosphatidylinositol 4,5-bisphosphate determine regulation of kir channels by diverse modulators.
2004,
Pubmed
,
Xenbase
Duan,
Verapamil blocks HERG channel by the helix residue Y652 and F656 in the S6 transmembrane domain.
2007,
Pubmed
,
Xenbase
Ehrlich,
Inward rectifier potassium currents as a target for atrial fibrillation therapy.
2008,
Pubmed
Ferrer,
Carvedilol inhibits Kir2.3 channels by interference with PIP₂-channel interaction.
2011,
Pubmed
Freeze,
State-dependent verapamil block of the cloned human Ca(v)3.1 T-type Ca(2+) channel.
2006,
Pubmed
Gaborit,
Regional and tissue specific transcript signatures of ion channel genes in the non-diseased human heart.
2007,
Pubmed
Gao,
Inhibition of ultra-rapid delayed rectifier K+ current by verapamil in human atrial myocytes.
2004,
Pubmed
Girmatsion,
Changes in microRNA-1 expression and IK1 up-regulation in human atrial fibrillation.
2009,
Pubmed
Hansen,
Structural basis of PIP2 activation of the classical inward rectifier K+ channel Kir2.2.
2011,
Pubmed
Hibino,
Inwardly rectifying potassium channels: their structure, function, and physiological roles.
2010,
Pubmed
Jones,
Selective phenylalkylamine block of I(Kr) over other K(+) currents in guinea-pig ventricular myocytes.
2000,
Pubmed
Karle,
Human cardiac inwardly-rectifying K+ channel Kir(2.1b) is inhibited by direct protein kinase C-dependent regulation in human isolated cardiomyocytes and in an expression system.
2002,
Pubmed
,
Xenbase
Kato,
Intracoronary verapamil rapidly terminates reperfusion tachyarrhythmias in acute myocardial infarction.
2004,
Pubmed
Kirchhof,
2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS.
2016,
Pubmed
Koepple,
Dual Mechanism for Inhibition of Inwardly Rectifying Kir2.x Channels by Quinidine Involving Direct Pore Block and PIP2-interference.
2017,
Pubmed
,
Xenbase
Laszlo,
Effect of verapamil on tachycardia-induced early cellular electrical remodeling in rabbit atrium.
2007,
Pubmed
Luo,
MicroRNA-26 governs profibrillatory inward-rectifier potassium current changes in atrial fibrillation.
2013,
Pubmed
López-Izquierdo,
Mechanisms for Kir channel inhibition by quinacrine: acute pore block of Kir2.x channels and interference in PIP2 interaction with Kir2.x and Kir6.2 channels.
2011,
Pubmed
López-Izquierdo,
The antimalarial drug mefloquine inhibits cardiac inward rectifier K+ channels: evidence for interference in PIP2-channel interaction.
2011,
Pubmed
Madeja,
Follicular tissues reduce drug effects on ion channels in oocytes of Xenopus laevis.
1997,
Pubmed
,
Xenbase
McTavish,
Verapamil. An updated review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension.
1989,
Pubmed
Myles,
Decreased inward rectifying K+ current and increased ryanodine receptor sensitivity synergistically contribute to sustained focal arrhythmia in the intact rabbit heart.
2015,
Pubmed
Nattel,
Arrhythmogenic ion-channel remodeling in the heart: heart failure, myocardial infarction, and atrial fibrillation.
2007,
Pubmed
Nerbonne,
Molecular physiology of cardiac repolarization.
2005,
Pubmed
Ninomiya,
Verapamil, a Ca2+ entry blocker, targets the pore-forming subunit of cardiac type KATP channel (Kir6.2).
2003,
Pubmed
Nogami,
Purkinje-related arrhythmias part I: monomorphic ventricular tachycardias.
2011,
Pubmed
Noujaim,
Up-regulation of the inward rectifier K+ current (I K1) in the mouse heart accelerates and stabilizes rotors.
2007,
Pubmed
Noujaim,
Specific residues of the cytoplasmic domains of cardiac inward rectifier potassium channels are effective antifibrillatory targets.
2010,
Pubmed
Orvos,
Evaluation of Possible Proarrhythmic Potency: Comparison of the Effect of Dofetilide, Cisapride, Sotalol, Terfenadine, and Verapamil on hERG and Native IKr Currents and on Cardiac Action Potential.
2019,
Pubmed
Ponce-Balbuena,
Tamoxifen inhibits inward rectifier K+ 2.x family of inward rectifier channels by interfering with phosphatidylinositol 4,5-bisphosphate-channel interactions.
2009,
Pubmed
Raphemot,
Discovery, characterization, and structure-activity relationships of an inhibitor of inward rectifier potassium (Kir) channels with preference for Kir2.3, Kir3.x, and Kir7.1.
2011,
Pubmed
,
Xenbase
Reynolds,
Trandolapril/verapamil sustained release: a review of its use in the treatment of essential hypertension.
2005,
Pubmed
Rodríguez-Menchaca,
The molecular basis of chloroquine block of the inward rectifier Kir2.1 channel.
2008,
Pubmed
Rolf,
Effects of antiarrhythmic drugs on cloned cardiac voltage-gated potassium channels expressed in Xenopus oocytes.
2000,
Pubmed
,
Xenbase
Schroder,
Chronic verapamil treatment remodels ICa,L in mouse ventricle.
2007,
Pubmed
Singh,
Electrophysiologic and hemodynamic effects of slow-channel blocking drugs.
1982,
Pubmed
Tristani-Firouzi,
Kir 2.1 channelopathies: the Andersen-Tawil syndrome.
2010,
Pubmed
Waldegger,
Effect of verapamil enantiomers and metabolites on cardiac K+ channels expressed in Xenopus oocytes.
1999,
Pubmed
,
Xenbase
Xia,
A Kir2.1 gain-of-function mutation underlies familial atrial fibrillation.
2005,
Pubmed
Xynogalos,
Class III antiarrhythmic drug dronedarone inhibits cardiac inwardly rectifying Kir2.1 channels through binding at residue E224.
2014,
Pubmed
,
Xenbase
Zhang,
Mechanism of block and identification of the verapamil binding domain to HERG potassium channels.
1999,
Pubmed
de Boer,
The anti-protozoal drug pentamidine blocks KIR2.x-mediated inward rectifier current by entering the cytoplasmic pore region of the channel.
2010,
Pubmed